Show simple item record

dc.contributor.authorGaleva, Slavyana
dc.contributor.authorKonstantinidou, Liountmila
dc.contributor.authorGil Mira, María del Mar 
dc.contributor.authorAkolekar, Ranjit
dc.contributor.authorNicolaides, Kypros H.
dc.date.accessioned2019-04-08T10:29:11Z
dc.date.available2019-04-08T10:29:11Z
dc.date.issued2018
dc.identifier.issn0960-7692spa
dc.identifier.urihttp://hdl.handle.net/10641/1599
dc.description.abstractObjective: To report on the routine clinical implementation of cell-free (cf)DNA analysis of maternal blood for trisomies 21, 18 and 13 contingent on the results of the first-trimester combined test in twin pregnancies. Methods: Screening for trisomies 21, 18 and 13 was carried out by a combination of maternal age, fetal nuchal translucency (NT) thickness, and serum free ß-hCG and PAPP-A at 11-13 weeks’ gestation in 959 twin pregnancies in two UK NHS hospitals. Women in the high-risk group (risk >1 in 100) were offered options of invasive testing, cfDNA testing or no further testing and those in the intermediate-risk group (risk 1 in 101 to 1 in 2500 in the first phase of the study and 1 in 101 to 1 in 500 in the second phase) were offered cfDNA or no further testing. The trisomic status of the pregnancies was determined by prenatal or postnatal karyotyping or examination of the neonates. Results: In 42 (4.4%) of the 959 pregnancies there was termination, miscarriage or stillbirth with no known karyotype or there was loss to follow up. The 917 pregnancies with known trisomic status of both twins, included 6 that were discordant for trisomy 21, 4 discordant for trisomy 18 and 896 with no trisomies 21, 18 or 13. Following combined screening, 47 (5.1%), 203 (22.2%) and 667 (72.7%) of the pregnancies were classified as high-risk, intermediate-risk and low-risk, respectively. The high-risk group included 5 (83.3%) cases of trisomy 21 and 3 (75.0%) of trisomy 18. The cfDNA test was carried out in 224 pregnancies and results were provided in 214 (95.5%); this group included 6 with trisomy 21, 3 with trisomy 18 and 206 with no trisomies 21, 18 or 13. The cfDNA test correctly classified as screen positive all 6 cases of trisomy 21 and 2 of the 3 with trisomy 18 and as screen negative for each of the trisomies all 206 unaffected pregnancies. Contingent screening, led to prenatal detection of all cases of trisomy 21 and 3 of 4 with trisomy 18. Conclusions: The study has demonstrated the feasibility of introducing cfDNA testing, contingent on the results of the first-trimester combined test for major trisomies, in a routine population of twin pregnancies.spa
dc.language.isoengspa
dc.publisherUltrasound in Obstetrics and Gynecologyspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectCell-free DNAspa
dc.subjectFirst-trimester screeningspa
dc.subjectCombined testspa
dc.subjectNon-invasive prenatal testingspa
dc.subjectTrisomy 21spa
dc.subjectTrisomy 18spa
dc.subjectTrisomy 13spa
dc.subjectTwin pregnancyspa
dc.titleRoutine first-trimester screening for fetal trisomies in twin pregnancies: cell-free DNA test contingent on results from the combined test.spa
dc.typearticlespa
dc.description.versionpre-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent248 KBspa
dc.identifier.doi10.1002/uog.20160spa


Files in this item

FilesSizeFormatView
cfDNA test.pdf247.5KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España